Search for other papers by Satoshi Koyama in
Google Scholar
PubMed
Search for other papers by Naritomo Miyake in
Google Scholar
PubMed
Search for other papers by Kazunori Fujiwara in
Google Scholar
PubMed
Search for other papers by Tsuyoshi Morisaki in
Google Scholar
PubMed
Search for other papers by Takahiro Fukuhara in
Google Scholar
PubMed
Center for Head and Neck Surgery, Kusatsu General Hospital, Kusatsu, Japan
Search for other papers by Hiroya Kitano in
Google Scholar
PubMed
Search for other papers by Hiromi Takeuchi in
Google Scholar
PubMed
Introduction Anaplastic thyroid cancer (ATC) is one of the most aggressive cancers, and death usually occurs within a few months after diagnosis [ 1 ]. Surgery is the most effective treatment to improve the prognosis [ 2 - 4 ]; however, most
Search for other papers by Janice Ser Huey Tan in
Google Scholar
PubMed
Search for other papers by Timothy Kwang Yong Tay in
Google Scholar
PubMed
Search for other papers by Enya Hui Wen Ong in
Google Scholar
PubMed
Search for other papers by Michael Fehlings in
Google Scholar
PubMed
Search for other papers by Daniel Shao-Weng Tan in
Google Scholar
PubMed
Search for other papers by Nadiah Binte Sukma in
Google Scholar
PubMed
Search for other papers by Eileen Xueqin Chen in
Google Scholar
PubMed
Search for other papers by Jen-Hwei Sng in
Google Scholar
PubMed
Search for other papers by Connie Siew Poh Yip in
Google Scholar
PubMed
Search for other papers by Kok Hing Lim in
Google Scholar
PubMed
Search for other papers by Darren Wan-Teck Lim in
Google Scholar
PubMed
Search for other papers by Narayanan Gopalakrishna Iyer in
Google Scholar
PubMed
Search for other papers by Jacqueline Siok Gek Hwang in
Google Scholar
PubMed
Search for other papers by Melvin Lee Kiang Chua in
Google Scholar
PubMed
Search for other papers by Mei-Kim Ang in
Google Scholar
PubMed
Introduction Anaplastic thyroid cancers (ATCs) are rare aggressive tumours, comprising only 1–2% of all thyroid cancers worldwide, and are typically associated with high mortality rates and a median overall survival (OS) of 5–12 months ( 1
Search for other papers by Inês Damásio in
Google Scholar
PubMed
Search for other papers by Joana Simões-Pereira in
Google Scholar
PubMed
Nova Medical School, Lisbon, Portugal
Search for other papers by Sara Donato in
Google Scholar
PubMed
Search for other papers by Mariana Horta in
Google Scholar
PubMed
Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed
Search for other papers by Miguel Rito in
Google Scholar
PubMed
Search for other papers by Pedro Gomes in
Google Scholar
PubMed
Nova Medical School, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Established facts Anaplastic thyroid carcinoma is one of the most aggressive cancers in humans and frequently presents with unressectable disease. Individualized therapies targeting specific molecular alterations are emerging
Search for other papers by Andrea Palermo in
Google Scholar
PubMed
Search for other papers by Andrea Napolitano in
Google Scholar
PubMed
Search for other papers by Daria Maggi in
Google Scholar
PubMed
Search for other papers by Anda Mihaela Naciu in
Google Scholar
PubMed
Search for other papers by Gaia Tabacco in
Google Scholar
PubMed
Search for other papers by Silvia Manfrini in
Google Scholar
PubMed
Search for other papers by Anna Crescenzi in
Google Scholar
PubMed
Search for other papers by Chiara Taffon in
Google Scholar
PubMed
Search for other papers by Francesco Pantano in
Google Scholar
PubMed
Search for other papers by Bruno Vincenzi in
Google Scholar
PubMed
Search for other papers by Guiseppe Tonini in
Google Scholar
PubMed
Search for other papers by Daniele Santini in
Google Scholar
PubMed
initially used for the treatment of malignant melanoma and then approved in other cancers, such as non-small cell lung cancer and clear cell renal cell carcinoma (ccRCC) [ 2 ]. More recently, a case of anaplastic thyroid cancer treated with vemurafenib and
Search for other papers by Alexis Lacout in
Google Scholar
PubMed
Search for other papers by Emmanuel Chamorey in
Google Scholar
PubMed
Search for other papers by Juliette Thariat in
Google Scholar
PubMed
Search for other papers by Mostafa El Hajjam in
Google Scholar
PubMed
Search for other papers by Carole Chevenet in
Google Scholar
PubMed
Search for other papers by Renaud Schiappa in
Google Scholar
PubMed
Search for other papers by Pierre Yves Marcy in
Google Scholar
PubMed
Introduction Thyroid carcinomas account for 1–1.5% of all cancers and have a pronounced female predominance (sex ratio F/M: 6–7 cases/1). The incidence of thyroid cancers is around 7.5 in females and 2.1 in males per year per 100
University of Lille, Lille, France
Search for other papers by Benjamin Chevalier in
Google Scholar
PubMed
Search for other papers by Oriane Karleskind in
Google Scholar
PubMed
University of Lille, Lille, France
Search for other papers by Arnaud Jannin in
Google Scholar
PubMed
Search for other papers by Olivier Farchi in
Google Scholar
PubMed
Search for other papers by Catherine Vermaut in
Google Scholar
PubMed
CRIStAL UMR CNRS 9189, University of Lille, Villeneuve-d’Ascq, France
Search for other papers by Alexandre Escande in
Google Scholar
PubMed
Search for other papers by Clio Baillet in
Google Scholar
PubMed
University of Lille, Lille, France
Institut National de la Santé et de la Recherche Médicale (INSERM), European Genomic Institute for Diabetes (EGID), CHU Lille, Lille, France
Search for other papers by Stéphanie Espiard in
Google Scholar
PubMed
University of Lille, Lille, France
Institut National de la Santé et de la Recherche Médicale (INSERM), European Genomic Institute for Diabetes (EGID), CHU Lille, Lille, France
Search for other papers by Marie-Christine Vantyghem in
Google Scholar
PubMed
Search for other papers by Bruno Carnaille in
Google Scholar
PubMed
Department of Pathology, Lille University Hospital, Lille, France
University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
Search for other papers by Emmanuelle Leteurtre in
Google Scholar
PubMed
Search for other papers by Christine Do Cao in
Google Scholar
PubMed
Established facts Anaplastic thyroid carcinoma represents the most aggressive variant of thyroid cancer. Prognosis is dismal. Classical treatment is based on radiotherapy and chemotherapy. Surgery is rarely feasible
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Tim Brandenburg in
Google Scholar
PubMed
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Philipp Muchalla in
Google Scholar
PubMed
University Duisburg-Essen, Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Sarah Theurer in
Google Scholar
PubMed
University Duisburg-Essen, Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Kurt Werner Schmid in
Google Scholar
PubMed
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Dagmar Führer in
Google Scholar
PubMed
NF1 mutations in anaplastic thyroid cancer . Endocrine . 2016 Dec 1 ; 54 ( 3 ): 733 – 41 . http://dx.doi.org/10.1007/s12020-016-1080-9 . 12 Subbiah V , Kreitman RJ , Wainberg ZA , Cho JY , Schellens JHM , Soria JC
Search for other papers by Noriyoshi Takahashi in
Google Scholar
PubMed
Search for other papers by Haruo Matsushita in
Google Scholar
PubMed
Search for other papers by Rei Umezawa in
Google Scholar
PubMed
Search for other papers by Takaya Yamamoto in
Google Scholar
PubMed
Search for other papers by Yojiro Ishikawa in
Google Scholar
PubMed
Search for other papers by Yu Katagiri in
Google Scholar
PubMed
Search for other papers by Shun Tasaka in
Google Scholar
PubMed
Search for other papers by Kazuya Takeda in
Google Scholar
PubMed
Search for other papers by Katsuya Fukui in
Google Scholar
PubMed
Search for other papers by Noriyuki Kadoya in
Google Scholar
PubMed
Search for other papers by Kengo Ito in
Google Scholar
PubMed
Search for other papers by Keiichi Jingu in
Google Scholar
PubMed
Introduction Anaplastic thyroid carcinoma (ATC) is a rare cancer and has a poor prognosis. Thyroid carcinoma accounts for only 1% of all malignant neoplasms, and ATC accounts for only 1.7% of all thyroid cancers [ 1 ]. All ATC patients are
Department of Endocrinology, Portuguese Institute of Oncology, Lisbon, Portugal
Search for other papers by Mafalda Marcelino in
Google Scholar
PubMed
Search for other papers by Pedro Marques in
Google Scholar
PubMed
Search for other papers by Luis Lopes in
Google Scholar
PubMed
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Search for other papers by João Jácome de Castro in
Google Scholar
PubMed
2040867 16 Aldinger KA, Samaan NA, Ibanez M, Hill CS Jr: Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 1978;41:2267-2275. 10.1002/1097-0142(197806)41:6<2267::AID-CNCR2820410627
Nuclear Medicine, Radiology Department, San Francisco VA Medical Center, San Francisco, Calif., USA
Search for other papers by C. Mari Aparici in
Google Scholar
PubMed
Search for other papers by T. Liu in
Google Scholar
PubMed
untreated and in older patients, it can dedifferentiate into more aggressive and less treatable anaplastic thyroid cancer. Rarely, differentiated papillary cancer metastasizes to the lungs and very rarely to the skeleton and brain. Likewise nonlocal lymph